Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID M BROWN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1548368509
CMS profile
342787
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$52,325.86

88 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID M BROWN

NPI 1548368509 · CMS profile ID 342787

Allopathic & Osteopathic Physicians / Ophthalmology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548368509?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID M BROWN, NPI 1548368509, CMS profile ID 342787. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548368509?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DAVID M BROWN, NPI 1548368509, CMS profile ID 342787. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548368509?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DAVID M BROWN, NPI 1548368509, CMS profile ID 342787, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1548368509?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

88 matching records · $52,325.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 88 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–88 of 88.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $28.4905/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132995990 CMS
Regeneron Healthcare Solutions, Inc. $125.0005/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114015372 CMS
Biogen, Inc. $18.4905/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104861422 CMS
Regeneron Healthcare Solutions, Inc. $31.4005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114015370 CMS
ABBVIE INC. $24.4905/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103376231 CMS
EyePoint Pharmaceuticals US, Inc. $52.3305/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089506928 CMS
EyePoint Pharmaceuticals US, Inc. $1,387.5005/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089507482 CMS
Ocular Therapeutix, Inc. $154.8605/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148197833 CMS
Regeneron Pharmaceuticals, Inc. $793.5004/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396890 CMS
Regeneron Pharmaceuticals, Inc. $793.5004/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396892 CMS
Astellas Pharma US Inc $18.5404/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139333304 CMS
Apellis Pharmaceuticals, Inc. $22.8204/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154019374 CMS
Astellas Pharma US Inc $34.1804/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139304912 CMS
Biogen, Inc. $28.8904/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104811107 CMS
Regeneron Pharmaceuticals, Inc. $224.1803/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396888 CMS
Astellas Pharma US Inc $34.8303/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139305138 CMS
Biogen, Inc. $29.7003/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104832422 CMS
Ocular Therapeutix, Inc. $190.6603/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148197837 CMS
ABBVIE INC. $18.8403/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103376229 CMS
Regeneron Pharmaceuticals, Inc. $1,058.0003/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396884 CMS
Regeneron Pharmaceuticals, Inc. $1,058.0003/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396886 CMS
Regeneron Healthcare Solutions, Inc. $164.4002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114015368 CMS
Apellis Pharmaceuticals, Inc. $4,887.0002/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154019380 CMS
Biogen, Inc. $21.7202/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104811105 CMS
Biogen, Inc. $28.3502/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104870542 CMS
Biogen, Inc. $2.4702/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104879346 CMS
Regeneron Healthcare Solutions, Inc. $15.5002/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114015366 CMS
Biogen, Inc. $4.9202/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104859716 CMS
Regeneron Pharmaceuticals, Inc. $27.0102/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396882 CMS
Apellis Pharmaceuticals, Inc. $75.5002/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154019360 CMS
Apellis Pharmaceuticals, Inc. $67.0502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154019384 CMS
Apellis Pharmaceuticals, Inc. $19.6002/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154019370 CMS
Apellis Pharmaceuticals, Inc. $100.8902/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154019372 CMS
Regeneron Pharmaceuticals, Inc. $1,058.0001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396878 CMS
Regeneron Pharmaceuticals, Inc. $3,174.0001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114396880 CMS
Regeneron Healthcare Solutions, Inc. $15.9801/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114015364 CMS
ASD Specialty Healthcare, LLC $133.8001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151420044 CMS
Apellis Pharmaceuticals, Inc. $47.8101/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154019382 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $29,795.88 42
PY2020 $100,628.95 52
PY2021 $40,534.61 35
PY2022 $47,932.14 70
PY2023 $82,706.15 90
PY2024 $52,325.86 88
PY2025 $159,751.81 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,705.02 2
PY2025 Principal investigator $19,513,460.01 1,699
PY2024 Recipient $1,750.00 1
PY2024 Principal investigator $11,800,547.70 828
PY2023 Recipient $12,927.43 3
PY2023 Principal investigator $5,064,965.90 455
PY2022 Recipient $22,135.52 8
PY2022 Principal investigator $4,336,658.95 295
PY2021 Recipient $2,434.27 3
PY2021 Principal investigator $4,544,492.39 287
PY2020 Recipient $1,375.85 1
PY2020 Principal investigator $4,038,411.76 213
PY2019 Recipient $3,617.25 3
PY2019 Principal investigator $1,852,708.30 105

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,701 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Roche TCRC, Inc. $45,341.00 12/31/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644717
Recipient Regeneron Pharmaceuticals, Inc. $431.65 12/25/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184115875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,956.95 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 12/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279836
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,568.00 12/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration No dispute reported 06/30/2026 1190311247
Principal investigator 1 Roche TCRC, Inc. $1,893.00 12/17/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644636
Principal investigator 1 SANOFI US SERVICES INC. $23,300.00 12/17/2025 Non-covered Recipient Entity
Retina Consultants Of Houston
Age-related macular degeneration No dispute reported 06/30/2026 1226100421
Principal investigator 1 SANOFI US SERVICES INC. $3,623.00 12/17/2025 Non-covered Recipient Entity
Retina Consultants Of Houston
Age-related macular degeneration No dispute reported 06/30/2026 1226100429
Principal investigator 1 Roche TCRC, Inc. $10,170.00 12/15/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,694.25 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,768.50 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,694.25 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.01 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184272781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184272907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273091
Principal investigator 1 Roche TCRC, Inc. $2,000.00 12/10/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644670
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 12/05/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242368741
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 12/05/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242368743
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 12/05/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242368745
Principal investigator 1 Roche TCRC, Inc. $3,715.00 12/05/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644617
Principal investigator 1 Roche TCRC, Inc. $18,807.00 12/05/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644626
Principal investigator 1 Roche TCRC, Inc. $1,325.50 12/05/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644630
Principal investigator 1 Roche TCRC, Inc. $2,139.60 12/05/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644641
Principal investigator 1 Roche TCRC, Inc. $16,623.00 12/05/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644644
Principal investigator 1 Roche TCRC, Inc. $13,505.00 12/05/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644651
Principal investigator 1 Roche TCRC, Inc. $520.00 12/05/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268251
Principal investigator 1 Hoffmann-La Roche Limited $14.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644406
Principal investigator 1 Hoffmann-La Roche Limited $3,000.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644408
Principal investigator 1 Hoffmann-La Roche Limited $14.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644411
Principal investigator 1 Hoffmann-La Roche Limited $3,093.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644417
Principal investigator 1 Hoffmann-La Roche Limited $3,093.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644421
Principal investigator 1 Hoffmann-La Roche Limited $1,500.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644423
Principal investigator 1 Hoffmann-La Roche Limited $14.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644426
Principal investigator 1 Hoffmann-La Roche Limited $269.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644429
Principal investigator 1 Hoffmann-La Roche Limited $500.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644433
Principal investigator 1 Hoffmann-La Roche Limited $1,067.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644438
Principal investigator 1 Hoffmann-La Roche Limited $2,067.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644442
Principal investigator 1 Hoffmann-La Roche Limited $581.00 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211644446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,917.35 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,120.85 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 12/01/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.00 11/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266563
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,196.81 11/24/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A First-in Human trial to study safety and tolerability of single rising intravitreal dOses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple intravitReal dosing (single-masked, raNdomized, sham-controlle No dispute reported 06/30/2026 1220803118
Principal investigator 1 Genentech, Inc. $1,743.00 11/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644337
Principal investigator 1 Genentech, Inc. $65.00 11/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $521.00 11/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 11/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261613
Principal investigator 1 Genentech, Inc. $114.00 11/14/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644319
Principal investigator 1 Roche TCRC, Inc. $17,832.00 11/14/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644610
Principal investigator 1 Roche TCRC, Inc. $5,780.00 11/14/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644622
Principal investigator 1 Genentech, Inc. $1,796.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,052.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259799
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257637
Principal investigator 1 Genentech, Inc. $14,936.00 11/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,052.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255035
Principal investigator 1 Hoffmann-La Roche Limited $59.50 10/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
Natural History Study in Diabetic Retinopathy No dispute reported 06/30/2026 1211644403
Principal investigator 1 Roche TCRC, Inc. $4,263.00 10/23/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644721
Principal investigator 1 Roche TCRC, Inc. $8,866.90 10/20/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644614
Principal investigator 1 Roche TCRC, Inc. $390.00 10/20/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644655
Principal investigator 1 Genentech, Inc. $1,796.00 10/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644315
Principal investigator 1 Roche TCRC, Inc. $398.00 10/17/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.92 10/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184250271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 10/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184250273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.90 10/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184250275
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 10/10/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242363511
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 10/10/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242363513
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 10/10/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242363515
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 10/10/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242363517
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 10/10/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242363519
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 10/10/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242363521
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 10/10/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242363523
Principal investigator 1 Janssen Research & Development, LLC $792.00 10/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175401557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/09/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184246055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184246057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,532.25 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,052.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184243935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,835.80 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,768.50 09/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242365
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $276.10 09/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242359022
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 09/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242359108
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 09/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242359110
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 09/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242359112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,917.35 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.64 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $73.72 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.70 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.88 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.22 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.42 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238816
Principal investigator 1 Roche TCRC, Inc. $7,970.00 09/16/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644592
Principal investigator 1 Roche TCRC, Inc. $260.00 09/16/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644597
Principal investigator 1 Roche TCRC, Inc. $1,972.10 09/16/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644604
Principal investigator 1 Roche TCRC, Inc. $1,566.00 09/15/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644601
Principal investigator 1 Genentech, Inc. $130.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 09/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235675
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $600.00 09/08/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $418.50 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $418.50 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $418.50 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235545
Principal investigator 1 Astellas Pharma Global Development $1,000.00 09/03/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185512
Principal investigator 1 Astellas Pharma Global Development $100.00 09/03/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,605.25 08/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,679.85 08/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,882.35 08/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,060.20 08/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $73.96 08/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232832
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 08/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175401562
Principal investigator 1 Genentech, Inc. $2,024.00 08/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644294
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.00 08/21/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409496
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 08/14/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409236
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 08/14/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409258
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $70.20 08/14/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409334
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 08/14/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409362
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 08/14/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409374
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 08/14/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409422
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 08/14/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409432
Principal investigator 1 Apellis Pharmaceuticals, Inc. $40.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363632
Principal investigator 1 Astellas Pharma Global Development $9,000.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185514
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,000.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409206
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409224
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.45 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409240
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $371.25 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409248
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $324.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409282
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $405.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409296
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.50 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409308
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,484.89 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409316
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,000.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409318
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $324.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409322
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.50 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409328
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $147.15 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409336
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,131.19 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409354
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.50 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409360
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $411.75 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409364
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,500.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409368
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $741.10 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409382
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.45 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409384
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $405.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409410
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,329.64 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409420
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $324.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409424
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.50 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409436
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409444
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $837.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409456
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $371.25 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409466
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,350.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409486
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.45 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409488
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.50 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409506
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,600.00 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409520
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.45 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409526
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $198.45 08/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227627
Principal investigator 1 Roche TCRC, Inc. $1,566.00 08/08/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.70 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.70 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225256
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225260
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225264
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225334
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225500
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225502
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225556
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,120.85 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,793.15 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,793.15 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224136
Principal investigator 1 Genentech, Inc. $1,796.00 08/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644286
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $55.72 07/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,205.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222156
Principal investigator 1 Genentech, Inc. $3,120.00 07/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211645067
Principal investigator 1 Genentech, Inc. $26,279.59 07/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211645079
Principal investigator 1 Genentech, Inc. $34,472.00 07/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211645347
Principal investigator 1 Roche TCRC, Inc. $7,849.70 07/28/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644586
Principal investigator 1 Genentech, Inc. $1,899.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $881.65 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218982
Principal investigator 1 Roche TCRC, Inc. $18,658.32 07/24/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644589
Principal investigator 1 Genentech, Inc. $12,405.00 07/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644297
Principal investigator 1 Genentech, Inc. $898.00 07/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644301
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353617
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353619
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353621
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353623
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353625
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353627
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353629
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353631
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353633
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353635
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 07/16/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215698
Principal investigator 1 Janssen Research & Development, LLC $3,564.00 07/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175401439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,152.90 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213648
Principal investigator 1 Genentech, Inc. $19,636.00 07/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1211644744
Principal investigator 1 Genentech, Inc. $12,722.00 07/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211645075
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,052.00 07/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242353017
Principal investigator 1 Janssen Research & Development, LLC $86.00 07/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175401452
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 06/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407860
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $82.19 06/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407886
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 06/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408274
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.50 06/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408474
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 06/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408476
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 06/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408520
Recipient Ocular Therapeutix, Inc. $9,273.37 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184210982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 06/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184210998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 06/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 06/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211569
Principal investigator 1 Roche TCRC, Inc. $976.00 06/26/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644534
Principal investigator 1 Roche TCRC, Inc. $1,210.84 06/26/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644543
Principal investigator 1 Roche TCRC, Inc. $1,750.00 06/26/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644551
Principal investigator 1 Roche TCRC, Inc. $9,080.00 06/26/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1211644561
Principal investigator 1 Roche TCRC, Inc. $5,500.00 06/26/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1211644564
Principal investigator 1 Roche TCRC, Inc. $232.00 06/26/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644575
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $33.43 06/20/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408082
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 06/20/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408160
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 06/20/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208931
Principal investigator 1 Apellis Pharmaceuticals, Inc. $200.00 06/11/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363684
Principal investigator 1 Roche TCRC, Inc. $5,500.00 06/10/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1211644538
Principal investigator 1 Roche TCRC, Inc. $2,425.00 06/10/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644568
Principal investigator 1 Roche TCRC, Inc. $2,651.00 06/09/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1211644546
Principal investigator 1 Roche TCRC, Inc. $17,695.00 06/09/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1211644549
Principal investigator 1 Roche TCRC, Inc. $2,339.00 06/09/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644579
Principal investigator 1 Janssen Research & Development, LLC $5,225.00 06/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175401417
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 05/28/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407578
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 05/28/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407668
Principal investigator 1 Genentech, Inc. $65.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644243
Principal investigator 1 Genentech, Inc. $898.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644252
Principal investigator 1 Genentech, Inc. $957.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644271
Principal investigator 1 Genentech, Inc. $898.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644279
Principal investigator 1 Genentech, Inc. $1,910.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199521
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 05/16/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363686
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 05/16/2025 Non-covered Recipient Entity
Retina Consultants of Houston, PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363688
Principal investigator 1 Roche TCRC, Inc. $8,000.00 05/13/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211644697
Principal investigator 1 Janssen Research & Development, LLC $5,440.00 05/08/2025 Non-covered Recipient Entity
Retina Consultants Of Houston Pllc
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene No dispute reported 06/30/2026 1175282361
Principal investigator 1 Roche TCRC, Inc. $2,028.80 05/08/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644530
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346767
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $35.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346769
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346809
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346811
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346813
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346815
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346817
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346819
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346821
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346823
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346867
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346869
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346871
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346873
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346875
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346877
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346879
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346917
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346919
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346921
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346923
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346925
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 05/07/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242346927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.52 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.92 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.90 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.35 05/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.66 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $59.87 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.05 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.65 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.88 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48.94 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.99 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184192485
Principal investigator 1 Genentech, Inc. $10,759.00 05/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644255
Principal investigator 1 Genentech, Inc. $5,335.00 05/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644266
Principal investigator 1 Roche TCRC, Inc. $9,200.00 05/01/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211644708
Principal investigator 1 Roche TCRC, Inc. $7,413.20 04/30/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644557
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 04/28/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187571
Principal investigator 1 Roche TCRC, Inc. $4,229.00 04/18/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211644701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 04/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183556
Principal investigator 1 Roche TCRC, Inc. $6,155.50 04/15/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211644693
Principal investigator 1 Roche TCRC, Inc. $12,032.00 04/11/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644554
Principal investigator 1 Roche TCRC, Inc. $2,886.00 04/11/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644571
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 04/04/2025 Non-covered Recipient Entity
BRAZOS RETINA CONSULTING, LLC
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220771303
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 04/03/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225402979
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 04/03/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225404445
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 04/03/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225404447
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 04/03/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225404794
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,800.00 04/03/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225406212
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 04/03/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225406852
Principal investigator 1 Roche TCRC, Inc. $4,864.00 04/03/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644704
Principal investigator 1 Roche TCRC, Inc. $110.09 04/03/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 04/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181052
Principal investigator 1 Roche TCRC, Inc. $35,908.64 03/31/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179296
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179364
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179486
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179648
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184180196
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $156.60 03/25/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403327
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $357.75 03/25/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405892
Principal investigator 1 Roche TCRC, Inc. $26,748.00 03/25/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644527
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 03/24/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184175758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184175760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184175762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184175764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184175766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/20/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184176686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.59 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $73.61 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.39 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.10 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71.92 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.91 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.87 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $82.88 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.87 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.82 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.96 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $145.95 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.08 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.58 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.88 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.23 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.88 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.66 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.89 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $102.61 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.76 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.88 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.56 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.89 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.95 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22.85 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.91 03/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184174844
Principal investigator 1 Roche TCRC, Inc. $9,898.80 03/19/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644493
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336599
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336601
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336603
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336605
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336607
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336609
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336611
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336713
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336715
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336717
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336719
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336721
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336723
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336725
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336727
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336823
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336825
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336827
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,846.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336829
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,493.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336831
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,466.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242336833
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337507
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337509
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337567
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337569
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337643
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,775.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337645
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337647
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $35.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337649
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337651
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 03/12/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242337797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172226
Principal investigator 1 Roche TCRC, Inc. $2,310.00 03/11/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1211644489
Principal investigator 1 Roche TCRC, Inc. $537.00 03/10/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644524
Principal investigator 1 Genentech, Inc. $4,610.00 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644232
Principal investigator 1 Genentech, Inc. $65.00 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $172.06 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $172.06 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.57 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $352.36 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.23 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $445.49 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.68 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.25 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $445.49 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.57 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $367.33 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184159723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $352.36 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.23 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.98 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.68 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $319.82 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $367.33 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.25 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.02 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.52 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.02 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $258.40 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $217.90 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.02 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.57 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.98 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $445.49 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184160345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.68 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.57 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.52 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $194.94 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $258.40 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162380
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $217.90 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $445.49 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $319.82 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162396
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.25 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $367.33 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162402
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $352.36 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.23 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.98 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.68 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $352.36 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $319.82 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184162768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.23 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.68 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $352.36 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $319.82 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $262.70 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.25 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.57 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $367.33 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.02 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $194.94 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163268
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $319.82 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $262.70 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163350
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $352.36 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.23 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184163390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.98 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.23 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.98 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.68 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $445.49 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.57 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $352.36 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169334
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.91 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.23 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.98 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.68 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $301.46 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $369.22 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $319.82 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.25 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.98 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.57 03/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169540
Principal investigator 1 Janssen Research & Development, LLC $36.00 03/06/2025 Non-covered Recipient Entity
Retina Consultants Of Houston Pllc
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene No dispute reported 06/30/2026 1175282677
Principal investigator 1 Roche TCRC, Inc. $76,292.82 03/06/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.56 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,624.15 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $761.50 03/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156969
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333270
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333274
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333276
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333278
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333280
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333300
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,623.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333302
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333304
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333306
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333308
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333310
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333312
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,835.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333314
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333316
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,958.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333318
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333320
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333322
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333324
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333326
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333328
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333330
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333332
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333338
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,493.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333340
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333342
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,466.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333346
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,846.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333348
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,623.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333350
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,958.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333352
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,493.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333356
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,466.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333358
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,156.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333360
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,623.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333362
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,958.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242333364
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242334594
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242334596
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242334598
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 03/03/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242334600
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/28/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403867
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/28/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405002
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/28/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405884
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,631.27 02/27/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225403235
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,271.27 02/27/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225406906
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 02/27/2025 Non-covered Recipient Entity
Retina Consultants Of Houston Pllc
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene No dispute reported 06/30/2026 1175281562
Principal investigator 1 Roche TCRC, Inc. $350.00 02/21/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644679
Principal investigator 1 Roche TCRC, Inc. $9,874.73 02/20/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644469
Principal investigator 1 Roche TCRC, Inc. $77,092.48 02/19/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644473
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 02/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston Pllc
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene No dispute reported 06/30/2026 1175281764
Principal investigator 1 Janssen Research & Development, LLC $14,290.00 02/13/2025 Non-covered Recipient Entity
Retina Consultants Of Houston Pllc
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene No dispute reported 06/30/2026 1175282010
Principal investigator 1 Alexion Pharmaceuticals, Inc. $77,735.70 02/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) No dispute reported 06/30/2026 1185550942
Principal investigator 1 Roche TCRC, Inc. $748.00 02/12/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644461
Principal investigator 1 Roche TCRC, Inc. $1,652.90 02/12/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644477
Principal investigator 1 Roche TCRC, Inc. $250.00 02/12/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644485
Principal investigator 1 Roche TCRC, Inc. $429.00 02/12/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644499
Principal investigator 1 Roche TCRC, Inc. $3,847.71 02/12/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644507
Principal investigator 1 Roche TCRC, Inc. $2,666.80 02/11/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644689
Principal investigator 1 Ocular Therapeutix, Inc. $1,467.05 02/07/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236769
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 01/30/2025 Non-covered Recipient Entity
Retina Consultants Of Houston PA-Bellaire
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404052
Principal investigator 1 Novartis Pharmaceuticals Corporation $80,078.90 01/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC RETINA CONSULTANTS OF TEXAS
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration No dispute reported 06/30/2026 1190300529
Principal investigator 1 Roche TCRC, Inc. $428.00 01/27/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644464
Principal investigator 1 Genentech, Inc. $11,898.00 01/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644223
Principal investigator 1 Roche TCRC, Inc. $421.75 01/24/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211644676
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242328965
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,835.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242328967
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242328969
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242328971
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242328973
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,835.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329037
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329039
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329041
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329043
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329045
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329047
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,835.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329049
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329051
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329119
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329121
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329123
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329125
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329127
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329193
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329195
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329197
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,775.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329199
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $35.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329201
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329203
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329205
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329207
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329267
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329269
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329271
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329273
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329275
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329277
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329279
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329349
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329351
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329353
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329355
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329357
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329359
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329361
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329363
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,761.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329421
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,493.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329423
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,466.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329425
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,156.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329427
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,846.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329429
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,156.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329431
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 01/22/2025 Non-covered Recipient Entity
COMMUNITY CLINICAL RESEARCH INC
ITI-007-451 No dispute reported 06/30/2026 1242329433
Principal investigator 1 Roche TCRC, Inc. $37,182.00 01/21/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644480
Principal investigator 1 Roche TCRC, Inc. $30,483.00 01/21/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644503
Principal investigator 1 Roche TCRC, Inc. $4,734.59 01/21/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 01/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184148337
Principal investigator 1 Roche TCRC, Inc. $6,369.06 01/14/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644510
Principal investigator 1 Roche TCRC, Inc. $7,784.00 01/14/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211644673
Principal investigator 1 Genentech, Inc. $7,118.00 01/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON
iAMD Observational Study No dispute reported 06/30/2026 1211644240
Principal investigator 1 Janssen Research & Development, LLC $86.00 01/09/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175401546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146971
Principal investigator 1 Roche TCRC, Inc. $12,652.35 01/07/2025 Non-covered Recipient Entity
Retina Consultants of Houston d/b/a Retina Consultants of Texas
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211644684
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $103,743.77 01/06/2025 Non-covered Recipient Entity
Community Clinical Research
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235997866
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,228,826.68 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration No dispute reported 06/30/2026 1190311249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $761.50 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,132.75 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,132.75 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,132.75 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,267.75 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,132.75 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $761.50 01/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144534